BridgeBio Oncology Therapeutics, Inc.BBOT
Price (close)
$3.95
Market cap
$316.7M
P/E
—
Revenue (TTM)
—
Net income
-$182.1M
Dividend yield
—
1-year total return
-66.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What BridgeBio Oncology Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$41,692 | -$74.3M | -$134.0M |
| Free cash flow | — | — | -$55.1M | -$114.5M |
More on BBOT.
- BridgeBio Oncology Therapeutics, Inc. summary
- BridgeBio Oncology Therapeutics, Inc. financial statements
- BridgeBio Oncology Therapeutics, Inc. key metrics
- BridgeBio Oncology Therapeutics, Inc. health scores and style box
- BridgeBio Oncology Therapeutics, Inc. earnings
- BridgeBio Oncology Therapeutics, Inc. dividends
- BridgeBio Oncology Therapeutics, Inc. valuation
- BridgeBio Oncology Therapeutics, Inc. ownership and insiders
- BridgeBio Oncology Therapeutics, Inc. peers
Figures from BridgeBio Oncology Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.